Fresenius Kabi and Vifor Pharma have formed a joint venture in China to provide patients access to vital blood management treatment. It will combine Vifor Pharma’s leading intravenous drug portfolio for the treatment of iron deficiency with Fresenius Kabi’s strong and long-year presence in the market to benefit both patients and the healthcare system in China. The joint venture will focus on marketing, market access and medical affairs activities whereas Fresenius Kabi will be fully responsible for the commercialization of the intravenous iron portfolio. The joint company will be 55% owned by Vifor Pharma and 45% by Fresenius Kabi. Financial terms were not disclosed.

Fresenius Kabi and Vifor Pharma have formed a joint venture in China to provide patients access to vital blood management treatment. It will combine Vifor Pharma’s leading intravenous drug portfolio for the treatment of iron deficiency with Fresenius Kabi’s strong and long-year presence in the market to benefit both patients and the healthcare system in China. The joint venture will focus on marketing, market access and medical affairs activities whereas Fresenius Kabi will be fully responsible for the commercialization of the intravenous iron portfolio. The joint company will be 55% owned by Vifor Pharma and 45% by Fresenius Kabi. Financial terms were not disclosed.

With the launch of a Glucagon Emergency Kit, Fresenius Kabi offers an FDA-approved and cost-effective alternative to treat severe hypoglycemic episodes in people with diabetes. This is the company’s first pharma product sold and used primarily outside hospitals in the U.S.

Top government and company officials joined local executives and employees as Fresenius Kabi inaugurated yesterday the major expansion of the company’s production site in the Dominican Republic. 

In Haina, just outside the Dominican Republic’s capital and biggest city, Santo Domingo, the company manufactures apheresis sets. These products are used, for example, to collect blood components such as platelets or plasma. Fresenius Kabi undertook the expansion to meet the rising demand for these high-quality disposables used for critically important donations.

President Danilo Medina of the Dominican Republic was an honored guest at the ceremony. Also in attendance were Mats Henriksson, CEO of Fresenius Kabi, and Dr. Christian Hauer, President Transfusion Medicine and Cell Therapies Division of Fresenius Kabi. 

Mats Henriksson highlighted that Fresenius Kabi is one of the leading international companies supplying transfusion medicines and cell therapies to blood services and hospitals. “We are proud to continue and further develop our decades-long presence in this region, and we are very excited about this expanded facility,” Henriksson said. “This is yet another step in improving the lives of chronically and critically ill people around the world. We all look forward to putting ever more leading-edge disposables and devices in the hands of the people who are caring for patients and collecting life-saving plasma donations.”

Christian Hauer said the plant expansion will strengthen the company’s role as a major global exporter of apheresis and plasma collection sets. “Broadening our production activities in the Dominican Republic will increase our ability to produce and supply essential products for patients around the globe,” Hauer said.

Fresenius Kabi’s first plant building at the Haina site, which opened in 1987, covers around 18,000 square meters (195,000 square feet). The expansion, in which Fresenius Kabi is investing more than €30 million, doubles the size of the site’s newer, second plant building to around 15,000 square meters (160,000 square feet). The new space houses advanced production equipment, plasma kit assembly lines and sterilization units that double the cleanroom and storage capacity. The site also includes a large warehouse.

A global healthcare company specializing in life-saving medicines and technologies for infusion, transfusion and clinical nutrition, Fresenius Kabi has almost 40,000 employees worldwide, including more than 3,500 in Haina. The life-saving disposables for transfusion medicine and cell technologies manufactured in Haina are exported to global markets to make a difference in the quality of life of patients worldwide. 

Fresenius Kabi, Bio-Techne and Wilson Wolf have formed a new joint venture to support researchers and biopharmaceutical companies in the field of cell and gene therapy. The joint venture is owned equally by the three partners and will focus on providing scalable manufacturing technologies and processes needed to develop and commercialize new cell and gene therapies. No other financial terms were disclosed.

Fresenius Kabi, Bio-Techne and Wilson Wolf have formed a new joint venture to support researchers and biopharmaceutical companies in the field of cell and gene therapy. The joint venture is owned equally by the three partners and will focus on providing scalable manufacturing technologies and processes needed to develop and commercialize new cell and gene therapies. No financial terms were disclosed.

Busulfan, a drug for certain blood cancers, expands the company’s broad oncology portfolio.

Dicyclomine Hydrochloride Injection, an antispasmodic agent, expands Fresenius Kabi’s large and growing generic critical care portfolio.  

Ertapenem, an antibiotic, expands Fresenius Kabi's anti-infective portfolio.

Fosaprepitant, an antiemetic, expands the company's large sterile injectable portfolio in oncology.